{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:43:30Z","timestamp":1759520610085,"version":"build-2065373602"},"reference-count":5,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,5,30]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>The clinical research pipeline is critical to ensuring continued development of novel treatments that can offer patients with cancer safe and effective options. Unfortunately, progress has slowed since the COVID-19 pandemic due to uncovered, systemic inefficiencies across critical processes. Towards initiating discussion on how to reinvigorate clinical research, the Society for Immunotherapy of Cancer (SITC) hosted a virtual summit that characterized issues and formed potential solutions. This commentary serves to highlight the crisis facing clinical research as well as stimulate field-wide discussion on how to better serve patients into the future.<\/jats:p>","DOI":"10.1136\/jitc-2023-008520","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T05:55:20Z","timestamp":1720677320000},"page":"e008520","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["A crisis in clinical research"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1609","authenticated-orcid":false,"given":"David S","family":"Hong","sequence":"first","affiliation":[{"name":"Division of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-9662","authenticated-orcid":false,"given":"Mario","family":"Sznol","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,7,11]]},"reference":[{"key":"2025100312155512000_12.7.e008520.1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/d41573-021-00190-9","article-title":"Clinical development times for innovative drugs","volume":"21","author":"Brown","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025100312155512000_12.7.e008520.2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/d41573-022-00030-4","article-title":"Challenges and opportunities in the Pd1\/Pdl1 inhibitor clinical trial landscape","volume":"21","author":"Upadhaya","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2025100312155512000_12.7.e008520.3","unstructured":"Mikulic M . Number of drugs in the R&Amp;Amp;D pipeline worldwide 2022 vs. 2023, by development phase. Statista; 2023. Available: https:\/\/www.statista.com\/statistics\/791288\/r-and-d-pipeline-drugs-worldwide-by-phase-development\/#:~:text=At%20the%20begin%20of%202022%2C%20there%20were%2011%2C351,in%20the%20pre-clinical%20phase%20of%20the%20R%26D%20pipeline"},{"key":"2025100312155512000_12.7.e008520.4","unstructured":"Novotech . Regulatory requirements for clinical trials: a comparison of Australia and the US. Pharmaceutical Technology. February 21, 2020; 2020. Available: \/\/www.pharmaceutical-technology.com\/sponsored\/regulatory-requirements-for-clinical-trials-a-comparison-of-australia-and-the-us\/"},{"key":"2025100312155512000_12.7.e008520.5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/17407745221147689","article-title":"Now is the time to fix the evidence generation system","volume":"20","author":"Califf","year":"2023","journal-title":"Clin Trials"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:16:05Z","timestamp":1759518965000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":5,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7,11]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/jitc-2023-008520"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008520","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}